multikinase inhibitor overall survival advantage
Published 4 years ago • 77 plays • Length 4:15Download video MP4
Download video MP3
Similar videos
-
3:50
fgfr-specific tkis versus multikinase inhibitors
-
10:02
role of the multikinase inhibitor regorafenib in metastatic colorectal cancer
-
57:12
targeted therapies (i.e.: multi-kinase inhibitors, ret, ntrk inhibitors) in advanced disease. 251
-
3:35
emerging multikinase inhibitors in hcc
-
1:13
overall survival data of the monarch-2 trial in hr /her2- breast cancer
-
1:10
immuno-oncology agents plus tyrosine kinase inhibitors?
-
5:56
tki therapy: impact of age and adverse events
-
15:57
part 2 investigator insights: emerging multikinase inhibitors in the treatment of thyroid cancers
-
5:16
cdk4/6 inhibitor abemaciclib plus fulvestrant improves overall survival in hr-positive/her2-nega...
-
13:43
part 1 investigator insights: emerging multikinase inhibitors in the treatment of thyroid cancers
-
6:49
achieving a durable response with regorafenib in mcrc
-
11:16
part 3 investigator insights: emerging multikinase inhibitors in the treatment of thyroid cancers
-
10:32
advancements in targeted therapies: new hope for advanced thyroid cancer patients
-
4:57
selpercatinib benefit for advanced, kinase inhibitor-naïve, ret-mutant medullary thyroid cancer
-
20:02
management of differentiated thyroid carcinoma in the era of targeted therapy
-
19:09
harnessing the kinome: multi-kinase inhibitors for the management of hepatocellular carcinoma
-
1:18:32
advanced gi cancers: identifying and targeting uncommon but actionable genomic alterations
-
8:41
use of vegf-targeted tyrosine kinase inhibitors
-
3:26
developments in immunotherapy & targeted treatment for mnsclc | tejas patil, md | esmo22 colorado